Bridgewater-based Amneal Pharmaceuticals signed a long-term license agreement with Orion Corp. to bring its portfolio of complex generic programs to most parts of Europe as well as Australia and New Zealand.
The financial terms of the agreement were not disclosed.
The initial portfolio will include a mix of generic products commercially available in the U.S., as well as select high-value pipeline products currently under development. These products will be registered throughout Europe, Australia and New Zealand starting in 2023, with launches expected over the coming years.
Chirag Patel and Chintu Patel, Amneal co-CEOs, stated: “International expansion is a key strategic priority for Amneal, and today’s announcement demonstrates our commitment to execute on that. As a company, we are extremely focused on finding partners who share our same values, ethics and ambitions, and we truly could not have found a better European partner than Orion. We are excited to bring our medicines to the second-largest global pharmaceutical market, and we hope that today is only the beginning of our work together.”
With its portfolio of essential medicines, Amneal experienced a very productive year in 2022. The company successfully launched 26 new generic products. In the fourth quarter of 2022 alone, it launched eight new generic products, including clindamycin phosphate gel 1%, ipratropium bromide nasal sprays and prednisolone sodium phosphate oral solution.
The company is expecting to launch more than 30 new products in 2023.
